miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

Background: Sorafenib constitutes a suitable treatment alternative for patients with advanced hepatocellular carcinoma (HCC) in whom atezolizumab + bevacizumab therapy is contraindicated. The aim of the study was the identification of a miRNA signature in liquid biopsy related to sorafenib response....

Full description

Bibliographic Details
Main Authors: Patricia de la Cruz-Ojeda, Tobias Schmid, Loreto Boix, Manuela Moreno, Víctor Sapena, Juan M. Praena-Fernández, Francisco J. Castell, Juan Manuel Falcón-Pérez, María Reig, Bernhard Brüne, Miguel A. Gómez-Bravo, Álvaro Giráldez, Jordi Bruix, María T. Ferrer, Jordi Muntané
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Cells
Subjects:
extracellular vesicle
hepatocellular carcinoma
miRNA
liquid biopsy
Sorafenib
Online Access:https://www.mdpi.com/2073-4409/11/17/2673

Internet

https://www.mdpi.com/2073-4409/11/17/2673

Similar Items